# Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia

> **NCT01213836** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 75 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Seroquel XR- quetiapine fumarate extended release
- **DRUG:** Seroquel IR - quetiapine fumarate
- **DRUG:** Placebo matching Seroquel XR
- **DRUG:** Placebo matching Seroquel IR

## Key facts

- **NCT ID:** NCT01213836
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2012-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01213836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01213836, "Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01213836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*